icon
icon
icon
icon
Upgrade
icon

GlaxoSmithKline's (GSK.US) asthma drug may treat chronic lung disease or open up new growth avenues

AInvestFriday, Sep 6, 2024 6:30 am ET
1min read

GlaxoSmithKline's (GSK.US) best-selling asthma drug Nucala has shown positive results in treating another chronic lung disease, potentially opening up a new growth path for the product.

Nucala, first approved in the U.S. in 2015 for severe asthma, is now the company's top performer, with sales of £1.7bn ($2.24bn) last year.

The British drugmaker said a late-stage trial in some adults with chronic obstructive pulmonary disease showed Nucala had a statistically significant and clinically meaningful reduction in the rate of moderate and severe exacerbations compared with a placebo group, after two years of treatment.

Chronic obstructive pulmonary disease, or COPD, is a life-threatening inflammatory respiratory disease that causes airflow blockage and affects more than 300 million people worldwide. Exacerbations, which can be recurrent or sudden worsening of symptoms, damage the lungs and require hospitalization. GSK said this could constitute a vicious cycle of overall health deterioration, symptom worsening, quality-of-life decline and rising mortality.

As of writing, GSK was up 0.63% before the market opened, up 19% over the past year.

Notably, there had been no new therapies for the disease for more than a decade until recently, when France's Sanofi's (SNY.US) Dupixent was approved as an add-on treatment for some COPD patients in Europe.

GSK said the trial, which involved 806 people, used Nucala's monoclonal antibody in addition to inhaler maintenance therapy. The drugmaker released key data from the study, with full results to be published later.

Disclaimer: the above is a summary showing certain market information. AInvest is not responsible for any data errors, omissions or other information that may be displayed incorrectly as the data is derived from a third party source. Communications displaying market prices, data and other information available in this post are meant for informational purposes only and are not intended as an offer or solicitation for the purchase or sale of any security. Please do your own research when investing. All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit, or protect against loss in a down market.